Key Points

  • Bosutinib had manageable toxicity and acceptable tolerability, with adverse events distinct from that of other tyrosine kinase inhibitors.

  • Adverse events were primarily characterized by early-onset gastrointestinal events that were low grade, transient, and manageable.

Abstract

Bosutinib is an oral, dual SRC/ABL tyrosine kinase inhibitor (TKI) with clinical activity in Philadelphia chromosome–positive (Ph+) leukemia. We assessed the safety and tolerability of bosutinib 500 mg per day in a phase 1/2 study in chronic-phase (CP) chronic myeloid leukemia (CML) or advanced Ph+ leukemia following resistance/intolerance to imatinib and possibly other TKIs. Patient cohorts included second-line CP CML (n = 286), third-/fourth-line CP CML (n = 118), and advanced leukemia (n = 166). Median bosutinib duration was 11.1 (range, 0.03-83.4) months. Treatment-emergent adverse events (TEAEs) in each cohort were primarily gastrointestinal (diarrhea [86%/83%/74%], nausea [46%/48%/48%], and vomiting [37%/38%/43%]). Diarrhea presented early, with few (8%) patients experiencing grade 3/4 events; dose reduction due to diarrhea occurred in 6% of affected patients. Grade 3/4 myelosuppression TEAEs were reported in 41% of patients; among affected patients, 46% were managed with bosutinib interruption and 32% with dose reduction. Alanine aminotransferase elevation TEAEs occurred in 17% of patients (grade 3/4, 7%); among patients managed with dose interruption, bosutinib rechallenge was successful in 74%. Bosutinib demonstrated acceptable safety with manageable toxicities in Ph+ leukemia. This trial (NCT00261846) was registered at www.ClinicalTrials.gov (this manuscript is based on a different data snapshot from that in ClinicalTrials.gov).

Introduction

Tyrosine kinase inhibitors (TKIs) designed to inhibit the BCR-ABL oncoprotein are the backbone of treatment of all phases of Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML)1,2  and acute lymphoblastic leukemia (ALL).3  However, TKIs are associated with toxicity that may prevent patients from maintaining drug intensity, limiting therapeutic benefit. Indefinite TKI treatment duration makes tolerability and manageability of these adverse events (AEs) essential to therapeutic success. Familiarity with these AEs can aid monitoring and early identification of drug toxicity and appropriate intervention, including TKI dose modifications and concomitant medication support.

Imatinib, a TKI with specificity for BCR-ABL, as well as KIT and platelet-derived growth factor receptor (PDGFR), has been the standard of care for CML patients.4,5  However, many patients cannot tolerate imatinib because of toxicities, including gastrointestinal symptoms, arthralgia/myalgia, rash, fatigue, and myelosuppression.6-8  Intolerance also occurs with the second-generation TKIs dasatinib9  and nilotinib10  as first-line CML treatment. Thus, safety and tolerability of each TKI may influence treatment selection.

Bosutinib (SKI-606) is an oral, dual competitive SRC and ABL TKI with minimal activity against PDGFR or KIT.11,12  In a phase 1/2 study, bosutinib demonstrated efficacy in all phases of CML previously treated with imatinib alone or imatinib followed by dasatinib and/or nilotinib.13-15 

Bosutinib was associated with acceptable safety and tolerability across cohorts; mild or moderate gastrointestinal events and rash were the most common AEs.14,15  Although myelosuppression is universally observed during TKI therapy for CML and Ph+ ALL, nonhematologic AEs associated with bosutinib appear distinct from those of imatinib, dasatinib, and nilotinib.16-18  The current analysis from the same phase 1/2 study characterizes toxicities associated with bosutinib and describes toxicity management in Ph+ leukemia patients. Toxicity was assessed in patients receiving bosutinib as chronic-phase (CP) second-line (CP2L) or third-/fourth-line (CP3L) therapy and in patients with advanced (ADV) disease, including accelerated-phase (AP) or blast-phase (BP) CML and ALL.

Methods

Study design

This was an open-label, 2-part, multicenter, phase 1/2 study. Part 1 was a phase 1 dose-escalation study that determined a recommended dose of bosutinib 500 mg per day in primarily imatinib-resistant CP CML patients.14  No dose-limiting toxicities occurred in the 400- and 500-mg cohorts; in the 600-mg cohort, 1 of 12 patients experienced a dose-limiting toxicity (grade 3 rash, nausea, and vomiting) and additional patients experienced grade 2 alanine aminotransferase (ALT) elevation, grade 2 rash, and grade 3 diarrhea.14  Bosutinib 500 mg per day was selected as the part 2 starting dose, despite not reaching a protocol-defined maximum tolerated dose because of observed AEs with 600 mg per day. Clinical benefit was observed at all doses.

Part 2 is a phase 2 safety and efficacy evaluation of bosutinib 500 mg per day in CP, AP, or BP CML or Ph+ ALL patients with resistance or intolerance to imatinib and possibly dasatinib and/or nilotinib. Dose escalation to 600 mg per day was permitted for lack of efficacy (complete hematologic response not reached by week 8 or complete cytogenetic response not reached by week 12) if no drug-related grade 3/4 AE had occurred. Methodology and overall study results were reported previously for CP patients.14,15 

The protocol was approved by the central or institutional review board for each study site, and informed consent was obtained in accordance with the Declaration of Helsinki.

Patients

Patients were aged 18 years or older with cytogenetic or polymerase chain reaction confirmation of Ph+ CML or ALL, resistant to full-dose imatinib (CP CML, ≥600 mg; ADV, ≥800 mg) or intolerant to any dose of imatinib. Patients in the CP3L cohort were resistant to dasatinib 100 mg per day or nilotinib 800 mg per day and/or intolerant to any dose of dasatinib; patients in the ADV cohort may also have been resistant or intolerant to dasatinib and/or nilotinib. Additional criteria included Eastern Cooperative Oncology Group performance status score of 0 or 1 (2 permitted for the ADV cohort); adequate bone marrow (CP2L and CP3L cohorts), hepatic, and renal function (defined previously13,14 ); ≥7 days since any antiproliferative treatment (except hydroxyurea and anagrelide); ≥3 months postallogeneic hematopoietic stem cell transplantation; and recovery to grade 0 or 1 or to baseline from any toxicities associated with prior anticancer treatment (except alopecia).

Safety evaluations

The safety population included patients from parts 1 and 2 who received ≥1 bosutinib dose. AEs were assessed continually and graded for severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Laboratory tests, electrocardiograms (ECGs), vital signs, and physical examinations were performed; in some instances, abnormalities may have been reported as AEs. Treatment-emergent AEs (TEAEs) were defined as any event increasing in severity from baseline or any new event starting during bosutinib therapy or within 30 days of the last bosutinib dose.

Results

Patients

Five hundred seventy patients received bosutinib and were evaluated for safety. Patients were grouped by disease phase and by prior therapy into 3 cohorts (Table 1). The CP2L cohort (n = 286) included patients with CP CML following resistance (n = 196) or intolerance (n = 90) to prior imatinib only (ie, no other TKIs). The CP3L cohort (n = 118) included patients with CP CML following resistance/intolerance to prior imatinib plus dasatinib resistance (n = 38), dasatinib intolerance (n = 50), nilotinib resistance (n = 26), or nilotinib intolerance or exposure to all 3 TKIs (n = 4). The ADV cohort (n = 166) included patients with AP CML (n = 78), BP CML (n = 64), or ALL (n = 24) following resistance/intolerance to prior imatinib or to multiple prior TKIs (ie, imatinib plus dasatinib and/or nilotinib).

Table 1

Patient baseline demographic and clinical characteristics

Parameter CP2L CP3L ADV (n = 166) Total (n = 570) 
IM-R (n = 196) IM-I (n = 90)* Total (n = 286) IM-R/I + D-R (n = 38) IM-R/I + D-I (n = 50)* IM-R/I + N-R (n = 26) Total† (n = 118) 
Median age (range), y 51 (18-86) 55 (23-91) 53 (18-91) 56 (23-76) 57 (25-79) 53 (20-73) 56 (20-79) 50 (18-84) 53 (18-91) 
Male sex, n (%) 114 (58) 36 (40) 150 (52) 18 (47) 19 (38) 14 (54) 53 (45) 97 (58) 300 (53) 
Race, n (%)          
 White 131 (67) 55 (61) 186 (65) 28 (74) 38 (76) 17 (65) 86 (73) 103 (62) 375 (66) 
 Asian 42 (21) 22 (24) 64 (22) 4 (11) 9 (18) 2 (8) 15 (13) 35 (21) 114 (20) 
 Black 11 (6) 5 (6) 16 (6) 1 (3) 1 (2) 3 (12) 6 (5) 19 (11) 41 (7) 
 Other 12 (6) 8 (9) 20 (7) 5 (13) 2 (4) 4 (15) 11 (9) 9 (5) 40 (7) 
Median time since CML diagnosis(range), y 4.1 (0.6-15.1) 2.6 (0.1-13.6) 3.7 (0.1-15.1) 7.0 (1.2-17.6) 5.8 (0.6-18.3) 5.9 (1.2-16.3) 6.6 (0.6-18.3) 3.9 (0.1-22.1) 4.2 (0.1-22.1) 
ECOG performance status, n (%)‡          
 0 152 (78) 67 (74) 219 (77) 28 (74) 31 (62) 24 (92) 85 (72) 74 (45) 378 (66) 
 1 44 (22) 21 (23) 65 (23) 10 (26) 18 (36) 2 (8) 32 (27) 72 (43) 169 (30) 
 2 1 (1) 1 (<1) 20 (12) 21 (4) 
No. of prior therapies, n (%)          
 1 119 (61) 67 (74) 186 (65) 72 (43) 258 (45) 
 2 77 (39) 23 (26) 100 (35) 12 (32) 26 (52) 13 (50) 52 (44) 50 (30) 202 (35) 
 3 26 (68) 24 (48) 13 (50) 64 (54) 36 (22) 100 (18) 
 4 2 (2) 8 (5) 10 (2) 
Prior TKI therapy, n (%)          
 Imatinib only 196 (100) 90 (100) 286 (100) 98 (59) 384 (67) 
 Imatinib + dasatinib 38 (100) 50 (100) 88 (75) 40 (24) 128 (22) 
 Imatinib + nilotinib 26 (100) 27 (23) 12 (7) 39 (7) 
 Imatinib + dasatinib + nilotinib 3 (3) 16 (10) 19 (3) 
Other prior therapies, n (%)          
 Interferon 77 (39) 23 (26) 100 (35) 26 (68) 24 (48) 13 (50) 65 (55) 62 (37) 227 (40) 
 Stem cell transplant 6 (3) 2 (2) 8 (3) 2 (5) 5 (10) 9 (8) 14 (8) 31 (5) 
Parameter CP2L CP3L ADV (n = 166) Total (n = 570) 
IM-R (n = 196) IM-I (n = 90)* Total (n = 286) IM-R/I + D-R (n = 38) IM-R/I + D-I (n = 50)* IM-R/I + N-R (n = 26) Total† (n = 118) 
Median age (range), y 51 (18-86) 55 (23-91) 53 (18-91) 56 (23-76) 57 (25-79) 53 (20-73) 56 (20-79) 50 (18-84) 53 (18-91) 
Male sex, n (%) 114 (58) 36 (40) 150 (52) 18 (47) 19 (38) 14 (54) 53 (45) 97 (58) 300 (53) 
Race, n (%)          
 White 131 (67) 55 (61) 186 (65) 28 (74) 38 (76) 17 (65) 86 (73) 103 (62) 375 (66) 
 Asian 42 (21) 22 (24) 64 (22) 4 (11) 9 (18) 2 (8) 15 (13) 35 (21) 114 (20) 
 Black 11 (6) 5 (6) 16 (6) 1 (3) 1 (2) 3 (12) 6 (5) 19 (11) 41 (7) 
 Other 12 (6) 8 (9) 20 (7) 5 (13) 2 (4) 4 (15) 11 (9) 9 (5) 40 (7) 
Median time since CML diagnosis(range), y 4.1 (0.6-15.1) 2.6 (0.1-13.6) 3.7 (0.1-15.1) 7.0 (1.2-17.6) 5.8 (0.6-18.3) 5.9 (1.2-16.3) 6.6 (0.6-18.3) 3.9 (0.1-22.1) 4.2 (0.1-22.1) 
ECOG performance status, n (%)‡          
 0 152 (78) 67 (74) 219 (77) 28 (74) 31 (62) 24 (92) 85 (72) 74 (45) 378 (66) 
 1 44 (22) 21 (23) 65 (23) 10 (26) 18 (36) 2 (8) 32 (27) 72 (43) 169 (30) 
 2 1 (1) 1 (<1) 20 (12) 21 (4) 
No. of prior therapies, n (%)          
 1 119 (61) 67 (74) 186 (65) 72 (43) 258 (45) 
 2 77 (39) 23 (26) 100 (35) 12 (32) 26 (52) 13 (50) 52 (44) 50 (30) 202 (35) 
 3 26 (68) 24 (48) 13 (50) 64 (54) 36 (22) 100 (18) 
 4 2 (2) 8 (5) 10 (2) 
Prior TKI therapy, n (%)          
 Imatinib only 196 (100) 90 (100) 286 (100) 98 (59) 384 (67) 
 Imatinib + dasatinib 38 (100) 50 (100) 88 (75) 40 (24) 128 (22) 
 Imatinib + nilotinib 26 (100) 27 (23) 12 (7) 39 (7) 
 Imatinib + dasatinib + nilotinib 3 (3) 16 (10) 19 (3) 
Other prior therapies, n (%)          
 Interferon 77 (39) 23 (26) 100 (35) 26 (68) 24 (48) 13 (50) 65 (55) 62 (37) 227 (40) 
 Stem cell transplant 6 (3) 2 (2) 8 (3) 2 (5) 5 (10) 9 (8) 14 (8) 31 (5) 

CP, chronic-phase CML; 2L, second-line setting; 3L, third-/fourth-line setting; IM-R, imatinib resistant; IM-I, imatinib intolerant; IM-R/I, imatinib resistant/intolerant; D-R, dasatinib resistant; D-I, dasatinib intolerant; N-R, nilotinib resistant; ADV, advanced leukemia (accelerated-/blast-phase CML and acute lymphoblastic leukemia); ECOG, Eastern Cooperative Oncology Group.

*

The subgroups of patients with intolerance to prior TKI therapy.

Includes patients (n = 4) in whom prior imatinib therapy failed and who were intolerant to prior nilotinib or resistant or intolerant to prior nilotinib and dasatinib therapy (because of low n, data not shown separately).

ECOG performance status at baseline was missing for 1 patient each in the CP2L and CP3L cohorts.

Treatment summary

Median duration of bosutinib treatment across cohorts (analysis cutoff based on an interim unlocked database: May 15, 2013) was 11.1 (range, 0.03-83.4) months (CP2L, 24.8 [0.2-83.4] months; CP3L, 8.5 [0.2-78.1] months; ADV, 4.0 [0.03-77.9] months). The time from the last patient’s first dose to the cutoff was ≥48 months for CP2L and ≥36 months for CP3L and ADV.

Across cohorts, dose reductions and interruptions due to AEs occurred in 45% and 65% of patients, respectively, and were more common in CP2L (49% and 72%) and CP3L (50% and 66%) cohorts vs the ADV cohort (34% and 51%) (Table 2), likely reflecting differences in bosutinib exposure and treatment duration. More CP2L and CP3L patients intolerant vs resistant to prior TKIs had dose reductions and interruptions; intolerant patients were more likely to discontinue bosutinib treatment because of AEs, particularly thrombocytopenia (Table 2). Treatment interruptions due to AEs occurring ≤4 weeks after bosutinib initiation were comparable among the overall CP2L, CP3L, and ADV cohorts but were more common in CP2L and CP3L patients intolerant vs resistant to prior TKIs (Table 2).

Table 2

Treatment modifications and discontinuations due to AEs

Parameter, n (%) or median (range) CP2L CP3L ADV (n = 166) Total (n = 570) 
IM-R (n = 196) IM-I (n = 90)* Total (n = 286) IM-R/I + D-R (n = 38) IM-R/I + D-I (n = 50)* IM-R/I + N-R (n = 26) Total† (n = 118) 
Patients with ≥1 dose reduction‡,§ 87 (44) 52 (58) 139 (49) 13 (34) 32 (64) 13 (50) 59 (50) 57 (34) 255 (45) 
 No. dose reductions per patient||          
  1 45 (23) 33 (37) 78 (27) 10 (26) 16 (32) 10 (39) 36 (31) 32 (19) 146 (26) 
  2 37 (19) 15 (17) 52 (18) 2 (5) 13 (26) 2 (8) 18 (15) 21 (13) 91 (16) 
  ≥3 5 (3) 4 (4) 9 (3) 1 (3) 3 (6) 1 (4) 5 (4) 4 (2) 18 (3) 
Patients with ≥1 dose interruption 130 (66) 75 (83) 205 (72) 19 (50) 40 (80) 16 (62) 78 (66) 85 (51) 368 (65) 
 No. dose interruptions per patient          
  1 51 (26) 34 (38) 85 (30) 11 (29) 14 (28) 6 (23) 32 (27) 40 (24) 157 (28) 
  2 33 (17) 21 (23) 54 (19) 3 (8) 11 (22) 5 (19) 19 (16) 21 (13) 94 (17) 
  3 21 (11) 7 (8) 28 (10) 1 (3) 5 (10) 2 (8) 9 (8) 10 (6) 47 (8) 
  ≥4 25 (13) 13 (14) 38 (13) 4 (11) 10 (20) 3 (12) 18 (15) 14 (8) 70 (12) 
 Median cumulative duration of interruption (range), d 21.5 (1-582) 22.0 (1-429) 22.0 (1-582) 24.0 (1-144) 29.5 (1-181) 28.0 (1-150) 27.0 (1-181) 20.0 (1-257) 22.0 (1-582) 
Early (≤4 wk) interruptions 53 (27) 38 (42) 91 (32) 8 (21) 19 (38) 5 (19) 32 (27) 52 (31) 175 (31) 
Treatment discontinuation¶ 30 (15) 34 (38) 64 (22) 6 (16) 20 (40) 3 (12) 29 (25) 30 (18) 123 (22) 
 Thrombocytopenia# 6 (3) 11 (12) 17 (6) 1 (3) 7 (14) 8 (7) 5 (3) 30 (5) 
 Increased ALT 3 (2) 4 (4) 7 (2) 1 (2) 2 (8) 3 (3) 3 (2) 13 (2) 
 Neutropenia# 2 (1) 6 (7) 8 (3) 3 (8) 1 (2) 1 (4) 5 (4) 13 (2) 
 Diarrhea 3 (2) 1 (1) 4 (1) 1 (3) 1 (2) 2 (2) 6 (1) 
 Vomiting 1 (1) 2 (2) 3 (1) 1 (3) 2 (4) 3 (3) 1 (1) 7 (1) 
 Increased AST 1 (1) 1 (1) 2 (1) 1 (4) 1 (1) 1 (1) 4 (1) 
 Cardiac failure 1 (1) 1 (<1) 2 (4) 2 (2) 3 (1) 
 Dyspnea 1 (1) 1 (<1) 1 (2) 1 (1) 2 (1) 4 (1) 
 Pleural effusion 1 (1) 1 (<1) 1 (2) 1 (1) 2 (1) 4 (1) 
 Pulmonary fibrosis 1 (1) 1 (<1) 2 (1) 3 (1) 
 Anemia# 2 (2) 2 (1) 1 (3) 1 (2) 2 (2) 1 (1) 5 (1) 
 Myocardial infarction 1 (3) 1 (1) 1 (1) 2 (<1) 
 Pneumonia 1 (1) 1 (<1) 1 (1) 2 (<1) 
 Rash 1 (1) 2 (2) 3 (1) 3 (1) 
 Pericardial effusion 1 (2) 1 (1) 3 (2) 4 (1) 
Parameter, n (%) or median (range) CP2L CP3L ADV (n = 166) Total (n = 570) 
IM-R (n = 196) IM-I (n = 90)* Total (n = 286) IM-R/I + D-R (n = 38) IM-R/I + D-I (n = 50)* IM-R/I + N-R (n = 26) Total† (n = 118) 
Patients with ≥1 dose reduction‡,§ 87 (44) 52 (58) 139 (49) 13 (34) 32 (64) 13 (50) 59 (50) 57 (34) 255 (45) 
 No. dose reductions per patient||          
  1 45 (23) 33 (37) 78 (27) 10 (26) 16 (32) 10 (39) 36 (31) 32 (19) 146 (26) 
  2 37 (19) 15 (17) 52 (18) 2 (5) 13 (26) 2 (8) 18 (15) 21 (13) 91 (16) 
  ≥3 5 (3) 4 (4) 9 (3) 1 (3) 3 (6) 1 (4) 5 (4) 4 (2) 18 (3) 
Patients with ≥1 dose interruption 130 (66) 75 (83) 205 (72) 19 (50) 40 (80) 16 (62) 78 (66) 85 (51) 368 (65) 
 No. dose interruptions per patient          
  1 51 (26) 34 (38) 85 (30) 11 (29) 14 (28) 6 (23) 32 (27) 40 (24) 157 (28) 
  2 33 (17) 21 (23) 54 (19) 3 (8) 11 (22) 5 (19) 19 (16) 21 (13) 94 (17) 
  3 21 (11) 7 (8) 28 (10) 1 (3) 5 (10) 2 (8) 9 (8) 10 (6) 47 (8) 
  ≥4 25 (13) 13 (14) 38 (13) 4 (11) 10 (20) 3 (12) 18 (15) 14 (8) 70 (12) 
 Median cumulative duration of interruption (range), d 21.5 (1-582) 22.0 (1-429) 22.0 (1-582) 24.0 (1-144) 29.5 (1-181) 28.0 (1-150) 27.0 (1-181) 20.0 (1-257) 22.0 (1-582) 
Early (≤4 wk) interruptions 53 (27) 38 (42) 91 (32) 8 (21) 19 (38) 5 (19) 32 (27) 52 (31) 175 (31) 
Treatment discontinuation¶ 30 (15) 34 (38) 64 (22) 6 (16) 20 (40) 3 (12) 29 (25) 30 (18) 123 (22) 
 Thrombocytopenia# 6 (3) 11 (12) 17 (6) 1 (3) 7 (14) 8 (7) 5 (3) 30 (5) 
 Increased ALT 3 (2) 4 (4) 7 (2) 1 (2) 2 (8) 3 (3) 3 (2) 13 (2) 
 Neutropenia# 2 (1) 6 (7) 8 (3) 3 (8) 1 (2) 1 (4) 5 (4) 13 (2) 
 Diarrhea 3 (2) 1 (1) 4 (1) 1 (3) 1 (2) 2 (2) 6 (1) 
 Vomiting 1 (1) 2 (2) 3 (1) 1 (3) 2 (4) 3 (3) 1 (1) 7 (1) 
 Increased AST 1 (1) 1 (1) 2 (1) 1 (4) 1 (1) 1 (1) 4 (1) 
 Cardiac failure 1 (1) 1 (<1) 2 (4) 2 (2) 3 (1) 
 Dyspnea 1 (1) 1 (<1) 1 (2) 1 (1) 2 (1) 4 (1) 
 Pleural effusion 1 (1) 1 (<1) 1 (2) 1 (1) 2 (1) 4 (1) 
 Pulmonary fibrosis 1 (1) 1 (<1) 2 (1) 3 (1) 
 Anemia# 2 (2) 2 (1) 1 (3) 1 (2) 2 (2) 1 (1) 5 (1) 
 Myocardial infarction 1 (3) 1 (1) 1 (1) 2 (<1) 
 Pneumonia 1 (1) 1 (<1) 1 (1) 2 (<1) 
 Rash 1 (1) 2 (2) 3 (1) 3 (1) 
 Pericardial effusion 1 (2) 1 (1) 3 (2) 4 (1) 

Abbreviations are explained in Table 1.

*

The subgroups of patients with intolerance to prior TKI therapy.

Includes patients (n = 4) in whom prior imatinib therapy failed and who were intolerant to prior nilotinib therapy or resistant or intolerant to prior nilotinib and dasatinib therapy (because of low n, data not shown separately).

Dose reduction defined as a decrease in the dose level from the previous dose level administered.

§

For patients who started bosutinib treatment at a dose of 500 mg per day, dose could have been reduced to 400 mg per day because of toxicity and then subsequently escalated to 500 mg per day or reduced further to 300 mg per day. Patients whose dose was escalated to 500 mg per day could have had another dose reduction due to toxicity at another time; therefore, patients could have had multiple dose reductions to 400 or 300 mg per day.

||

Subcategory percentages may not add to the total due to rounding.

All AEs leading to treatment discontinuation in ≥1.0% of patients in the CP2L, CP3L, or ADV cohorts are shown in the table.

#

Individual hematologic AEs were clustered with the related terms from investigations.

Median cumulative duration of dose reduction to 400 mg per day was 88 days (range, 1-2323 days) (CP2L: 169 days; CP3L: 63.5 days; ADV: 59.5 days) and 127 days (range, 1-1480 days) to 300 mg per day (CP2L: 115 days; CP3L: 180 days; ADV: 158 days). Among patients with bosutinib dose reduction to 400 mg per day in the CP2L and CP3L cohorts, 18 of 130 (14%) and 4 of 52 (8%), respectively, had a major cytogenetic response (MCyR) before and after reduction, and an additional 56 of 130 (43%) and 15 of 52 (29%) patients first achieved MCyR after reduction; 3 CP2L patients and 2 CP3L patients lost their previously attained MCyR after reduction. Among those with dose reduction to 300 mg per day in the CP2L and CP3L cohorts, 17 of 49 (35%) and 4 of 21 (19%) patients had MCyR both before and after reduction; 8 of 49 (16%) and 4 of 21 (19%) patients first achieved MCyR after reduction; 2 and 0 patients lost their previously attained MCyR after reduction. For ADV patients with bosutinib dose reduction to 400 or 300 mg per day, 11 of 50 (22%) and 4 of 23 (17%) patients had an overall hematologic response (OHR) before and after first reduction; 15 of 50 (30%) and 3 of 23 (13%) first achieved OHR after reduction; 3 and 7 lost their previously attained OHR after reduction. Of 558 patients who received an initial dose of bosutinib 400 or 500 mg per day, 92 (17%) had dose escalation to 600 mg per day due to lack of efficacy; median treatment duration at 600 mg per day was 159 (range, 4-1811) days.

At the time of analysis, 147 (26%) patients were receiving treatment. Disease progression was the most common reason for treatment discontinuation (25%), followed by AEs (22%). Rates of discontinuation due to AEs did not substantially differ across patient cohorts (Table 2); median time to bosutinib discontinuation due to AEs was 5.1 (range, 0.2-75.3) months. Of those who discontinued treatment because of an AE, 29% and 28% had their AE managed with bosutinib dose reduction to 300 or 400 mg per day, respectively, before discontinuation; 42% were not reduced to <500 mg per day before discontinuation. Of patients reduced to bosutinib 300 or 400 mg per day because of an AE, 12 of 93 (13%) and 41 of 232 (18%), respectively, later discontinued bosutinib because of progressive disease and 8 of 93 (9%) and 17 of 232 (7%) discontinued due to unsatisfactory response/lack of efficacy. Among 272 patients who had achieved/maintained an MCyR, treatment was discontinued for 139 (51%); more patients discontinued treatment in the ADV (84%) vs CP2L (38%) or CP3L (60%) cohorts. The most common reasons for treatment discontinuation among patients who had achieved/maintained an MCyR were disease progression (CP2L, 13%; CP3L, 15%; ADV, 46%) and AEs (10%, 23%, 18%).

Overall safety

Bosutinib toxicities were generally of mild to moderate severity and managed with concomitant medication, dose interruption and/or dose reduction, or resolved spontaneously. The most frequently reported TEAEs were gastrointestinal events (diarrhea, nausea, and vomiting) and thrombocytopenia; incidences did not substantially differ across cohorts overall (Table 3). Although diarrhea was common (82%), maximum severity was grade 1 (45%) or 2 (28%) in most patients; few experienced maximum grade 3 (8%) or 4 (<1%; 1 ADV patient) diarrhea. Based on differences of ≥10% for TEAEs occurring in ≥10% of patients, rash was more common and pyrexia less common in patients intolerant vs resistant to prior imatinib treatment in the CP2L cohort (Table 3). In the CP3L cohort, vomiting, rash, dyspnea, and pleural effusion were more common and neutropenia was less common in patients intolerant to prior dasatinib therapy vs patients resistant to prior TKI therapy (Table 3). Thrombocytopenia was most common in CP3L resistant to nilotinib. Grade 3/4 TEAEs reported in ≥10% of all patients were hematologic events, including thrombocytopenia (30%), anemia (14%), and neutropenia (14%; Table 3). Among 92 patients who were dose escalated to bosutinib 600 mg per day, generally no increases >5% were observed in the frequency or severity of individual TEAEs following dose escalation.

Table 3

TEAEs reported for ≥10% of patients

TEAE, n (%) CP2L CP3L ADV (n = 166) Total (n = 570)† 
IM-R (n = 196) IM-I (n = 90)* Total (n = 286) IM-R/I + D-R (n = 38) IM-R/I + D-I (n = 50)* IM-R/I + N-R (n = 26) Total (n = 118)† 
Diarrhea          
 All grades 168 (86) 77 (86) 245 (86) 30 (79) 42 (84) 22 (85) 98 (83) 122 (74) 465 (82) 
 Grade 3/4 19 (10) 10 (11) 29 (10) 3 (8) 5 (10) 2 (8) 10 (9) 8 (5) 47 (8) 
Nausea          
 All grades 85 (43) 47 (52) 132 (46) 20 (53) 23 (46) 12 (46) 57 (48) 80 (48) 269 (47) 
 Grade 3/4 1 (1) 3 (3) 4 (1) 1 (3) 1 (1) 3 (2) 8 (1) 
Vomiting          
 All grades 73 (37) 34 (38) 107 (37) 14 (37) 24 (48) 7 (27) 45 (38) 72 (43) 224 (39) 
 Grade 3/4 3 (2) 8 (9) 11 (4) 1 (3) 1 (1) 6 (4) 18 (3) 
Thrombocytopenia‡          
 All grades 77 (39) 43 (48) 120 (42) 11 (29) 19 (38) 13 (50) 45 (38) 74 (45) 239 (42) 
 Grade 3/4 45 (23) 29 (32) 74 (26) 7 (18) 16 (32) 8 (31) 31 (26) 65 (39) 170 (30) 
Rash          
 All grades 63 (32) 39 (43) 102 (36) 10 (26) 18 (36) 3 (12) 32 (27) 51 (31) 185 (33) 
 Grade 3/4 15 (8) 11 (12) 26 (9) 3 (6) 3 (3) 6 (4) 35 (6) 
Pyrexia          
 All grades 57 (29) 17 (19) 74 (26) 6 (16) 8 (16) 3 (12) 18 (15) 64 (39) 156 (27) 
 Grade 3/4 1 (1) 1 (1) 2 (1) 5 (3) 7 (1) 
Anemia‡          
 All grades 51 (26) 25 (28) 76 (27) 8 (21) 7 (14) 6 (23) 22 (19) 64 (39) 162 (28) 
 Grade 3/4 23 (12) 9 (10) 32 (11) 3 (8) 4 (8) 1 (4) 8 (7) 42 (25) 82 (14) 
Fatigue          
 All grades 49 (25) 25 (28) 74 (26) 8 (21) 14 (28) 2 (8) 27 (23) 35 (21) 136 (24) 
 Grade 3/4 1 (1) 2 (2) 3 (1) 1 (2) 2 (2) 7 (4) 12 (2) 
Abdominal pain          
 All grades 50 (26) 25 (28) 75 (26) 9 (24) 12 (24) 7 (27) 28 (24) 35 (21) 138 (24) 
 Grade 3/4 3 (2) 2 (2) 5 (2) 1 (2) 1 (1) 4 (2) 10 (2) 
Headache          
 All grades 35 (18) 18 (20) 53 (19) 8 (21) 14 (28) 8 (31) 31 (26) 31 (19) 115 (20) 
 Grade 3/4 1 (3) 3 (6) 4 (3) 7 (4) 11 (2) 
Cough          
 All grades 44 (22) 19 (21) 63 (22) 7 (18) 11 (22) 4 (15) 23 (20) 34 (21) 120 (21) 
 Grade 3/4 
Increased ALT          
 All grades 41 (21) 23 (26) 64 (22) 6 (16) 6 (12) 5 (19) 18 (15) 17 (10) 99 (17) 
 Grade 3/4 15 (8) 10 (11) 25 (9) 4 (8) 3 (12) 7 (6) 7 (4) 39 (7) 
Upper abdominal pain          
 All grades 41 (21) 17 (19) 58 (20) 8 (21) 9 (18) 4 (15) 21 (18) 17 (10) 96 (17) 
 Grade 3/4 1 (1) 1 (<1) 3 (2) 4 (1) 
Neutropenia‡          
 All grades 29 (15) 17 (19) 46 (16) 9 (24) 7 (14) 7 (27) 24 (20) 36 (22) 106 (19) 
 Grade 3/4 16 (8) 11 (12) 27 (9) 6 (16) 7 (14) 4 (15) 18 (15) 33 (20) 78 (14) 
Increased AST          
 All grades 37 (19) 18 (20) 55 (19) 2 (5) 3 (6) 4 (15) 9 (8) 17 (10) 81 (14) 
 Grade 3/4 6 (3) 5 (6) 11 (4) 1 (2) 2 (8) 3 (3) 5 (3) 19 (3) 
Arthralgia          
 All grades 30 (15) 15 (17) 45 (16) 5 (13) 10 (20) 6 (23) 21 (18) 22 (13) 88 (15) 
 Grade 3/4 2 (1) 1 (1) 3 (1) 1 (2) 1 (1) 1 (1) 5 (1) 
Decreased appetite          
 All grades 30 (15) 11 (12) 41 (14) 3 (8) 7 (14) 4 (15) 14 (12) 21 (13) 76 (13) 
 Grade 3/4 2 (1) 2 (1) 1 (2) 1 (1) 3 (1) 
Constipation          
 All grades 22 (11) 18 (20) 40 (14) 2 (5) 8 (16) 3 (12) 15 (13) 27 (16) 82 (14) 
 Grade 3/4 1 (1) 1 (<1) 1 (1) 2 (<1) 
Dyspnea          
 All grades 23 (12) 10 (11) 33 (12) 2 (5) 10 (20) 1 (4) 13 (11) 32 (19) 78 (14) 
 Grade 3/4 4 (2) 4 (1) 1 (2) 1 (1) 9 (5) 14 (3) 
Asthenia          
 All grades 25 (13) 16 (18) 41 (14) 2 (5) 1 (2) 4 (15) 8 (7) 20 (12) 69 (12) 
 Grade 3/4 6 (3) 6 (2) 1 (1) 7 (1) 
Back pain          
 All grades 22 (11) 17 (19) 39 (14) 5 (13) 5 (10) 3 (12) 14 (12) 15 (9) 68 (12) 
 Grade 3/4 1 (1) 1 (<1) 2 (4) 1 (4) 3 (3) 3 (2) 7 (1) 
Dizziness          
 All grades 17 (9) 9 (10) 26 (9) 5 (13) 8 (16) 2 (8) 16 (14) 21 (13) 63 (11) 
 Grade 3/4 1 (1) 1 (<1) 
Leukopenia‡          
 All grades 21 (11) 14 (16) 35 (12) 4 (11) 4 (3) 23 (14) 62 (11) 
 Grade 3/4 8 (4) 7 (8) 15 (5) 18 (11) 33 (6) 
Peripheral edema          
 All grades 18 (9) 13 (14) 31 (11) 1 (3) 5 (10) 4 (15) 11 (9) 17 (10) 59 (10) 
 Grade 3/4 1 (1) 1 (<1) 1 (1) 2 (<1) 
Nasopharyngitis          
 All grades 24 (12) 13 (14) 37 (13) 4 (11) 5 (10) 4 (15) 14 (12) 7 (4) 58 (10) 
 Grade 3/4 
Extremity pain          
 All grades 26 (13) 5 (6) 31 (11) 1 (3) 5 (10) 3 (12) 9 (8) 18 (11) 58 (10) 
 Grade 3/4 2 (1) 2 (1) 1 (1) 3 (1) 
Pleural effusion          
 All grades 18 (9) 5 (6) 23 (8) 5 (13) 12 (24) 1 (4) 18 (15) 16 (10) 57 (10) 
 Grade 3/4 4 (2) 2 (2) 6 (2) 2 (5) 2 (4) 4 (3) 7 (4) 17 (3) 
TEAE, n (%) CP2L CP3L ADV (n = 166) Total (n = 570)† 
IM-R (n = 196) IM-I (n = 90)* Total (n = 286) IM-R/I + D-R (n = 38) IM-R/I + D-I (n = 50)* IM-R/I + N-R (n = 26) Total (n = 118)† 
Diarrhea          
 All grades 168 (86) 77 (86) 245 (86) 30 (79) 42 (84) 22 (85) 98 (83) 122 (74) 465 (82) 
 Grade 3/4 19 (10) 10 (11) 29 (10) 3 (8) 5 (10) 2 (8) 10 (9) 8 (5) 47 (8) 
Nausea          
 All grades 85 (43) 47 (52) 132 (46) 20 (53) 23 (46) 12 (46) 57 (48) 80 (48) 269 (47) 
 Grade 3/4 1 (1) 3 (3) 4 (1) 1 (3) 1 (1) 3 (2) 8 (1) 
Vomiting          
 All grades 73 (37) 34 (38) 107 (37) 14 (37) 24 (48) 7 (27) 45 (38) 72 (43) 224 (39) 
 Grade 3/4 3 (2) 8 (9) 11 (4) 1 (3) 1 (1) 6 (4) 18 (3) 
Thrombocytopenia‡          
 All grades 77 (39) 43 (48) 120 (42) 11 (29) 19 (38) 13 (50) 45 (38) 74 (45) 239 (42) 
 Grade 3/4 45 (23) 29 (32) 74 (26) 7 (18) 16 (32) 8 (31) 31 (26) 65 (39) 170 (30) 
Rash          
 All grades 63 (32) 39 (43) 102 (36) 10 (26) 18 (36) 3 (12) 32 (27) 51 (31) 185 (33) 
 Grade 3/4 15 (8) 11 (12) 26 (9) 3 (6) 3 (3) 6 (4) 35 (6) 
Pyrexia          
 All grades 57 (29) 17 (19) 74 (26) 6 (16) 8 (16) 3 (12) 18 (15) 64 (39) 156 (27) 
 Grade 3/4 1 (1) 1 (1) 2 (1) 5 (3) 7 (1) 
Anemia‡          
 All grades 51 (26) 25 (28) 76 (27) 8 (21) 7 (14) 6 (23) 22 (19) 64 (39) 162 (28) 
 Grade 3/4 23 (12) 9 (10) 32 (11) 3 (8) 4 (8) 1 (4) 8 (7) 42 (25) 82 (14) 
Fatigue          
 All grades 49 (25) 25 (28) 74 (26) 8 (21) 14 (28) 2 (8) 27 (23) 35 (21) 136 (24) 
 Grade 3/4 1 (1) 2 (2) 3 (1) 1 (2) 2 (2) 7 (4) 12 (2) 
Abdominal pain          
 All grades 50 (26) 25 (28) 75 (26) 9 (24) 12 (24) 7 (27) 28 (24) 35 (21) 138 (24) 
 Grade 3/4 3 (2) 2 (2) 5 (2) 1 (2) 1 (1) 4 (2) 10 (2) 
Headache          
 All grades 35 (18) 18 (20) 53 (19) 8 (21) 14 (28) 8 (31) 31 (26) 31 (19) 115 (20) 
 Grade 3/4 1 (3) 3 (6) 4 (3) 7 (4) 11 (2) 
Cough          
 All grades 44 (22) 19 (21) 63 (22) 7 (18) 11 (22) 4 (15) 23 (20) 34 (21) 120 (21) 
 Grade 3/4 
Increased ALT          
 All grades 41 (21) 23 (26) 64 (22) 6 (16) 6 (12) 5 (19) 18 (15) 17 (10) 99 (17) 
 Grade 3/4 15 (8) 10 (11) 25 (9) 4 (8) 3 (12) 7 (6) 7 (4) 39 (7) 
Upper abdominal pain          
 All grades 41 (21) 17 (19) 58 (20) 8 (21) 9 (18) 4 (15) 21 (18) 17 (10) 96 (17) 
 Grade 3/4 1 (1) 1 (<1) 3 (2) 4 (1) 
Neutropenia‡          
 All grades 29 (15) 17 (19) 46 (16) 9 (24) 7 (14) 7 (27) 24 (20) 36 (22) 106 (19) 
 Grade 3/4 16 (8) 11 (12) 27 (9) 6 (16) 7 (14) 4 (15) 18 (15) 33 (20) 78 (14) 
Increased AST          
 All grades 37 (19) 18 (20) 55 (19) 2 (5) 3 (6) 4 (15) 9 (8) 17 (10) 81 (14) 
 Grade 3/4 6 (3) 5 (6) 11 (4) 1 (2) 2 (8) 3 (3) 5 (3) 19 (3) 
Arthralgia          
 All grades 30 (15) 15 (17) 45 (16) 5 (13) 10 (20) 6 (23) 21 (18) 22 (13) 88 (15) 
 Grade 3/4 2 (1) 1 (1) 3 (1) 1 (2) 1 (1) 1 (1) 5 (1) 
Decreased appetite          
 All grades 30 (15) 11 (12) 41 (14) 3 (8) 7 (14) 4 (15) 14 (12) 21 (13) 76 (13) 
 Grade 3/4 2 (1) 2 (1) 1 (2) 1 (1) 3 (1) 
Constipation          
 All grades 22 (11) 18 (20) 40 (14) 2 (5) 8 (16) 3 (12) 15 (13) 27 (16) 82 (14) 
 Grade 3/4 1 (1) 1 (<1) 1 (1) 2 (<1) 
Dyspnea          
 All grades 23 (12) 10 (11) 33 (12) 2 (5) 10 (20) 1 (4) 13 (11) 32 (19) 78 (14) 
 Grade 3/4 4 (2) 4 (1) 1 (2) 1 (1) 9 (5) 14 (3) 
Asthenia          
 All grades 25 (13) 16 (18) 41 (14) 2 (5) 1 (2) 4 (15) 8 (7) 20 (12) 69 (12) 
 Grade 3/4 6 (3) 6 (2) 1 (1) 7 (1) 
Back pain          
 All grades 22 (11) 17 (19) 39 (14) 5 (13) 5 (10) 3 (12) 14 (12) 15 (9) 68 (12) 
 Grade 3/4 1 (1) 1 (<1) 2 (4) 1 (4) 3 (3) 3 (2) 7 (1) 
Dizziness          
 All grades 17 (9) 9 (10) 26 (9) 5 (13) 8 (16) 2 (8) 16 (14) 21 (13) 63 (11) 
 Grade 3/4 1 (1) 1 (<1) 
Leukopenia‡          
 All grades 21 (11) 14 (16) 35 (12) 4 (11) 4 (3) 23 (14) 62 (11) 
 Grade 3/4 8 (4) 7 (8) 15 (5) 18 (11) 33 (6) 
Peripheral edema          
 All grades 18 (9) 13 (14) 31 (11) 1 (3) 5 (10) 4 (15) 11 (9) 17 (10) 59 (10) 
 Grade 3/4 1 (1) 1 (<1) 1 (1) 2 (<1) 
Nasopharyngitis          
 All grades 24 (12) 13 (14) 37 (13) 4 (11) 5 (10) 4 (15) 14 (12) 7 (4) 58 (10) 
 Grade 3/4 
Extremity pain          
 All grades 26 (13) 5 (6) 31 (11) 1 (3) 5 (10) 3 (12) 9 (8) 18 (11) 58 (10) 
 Grade 3/4 2 (1) 2 (1) 1 (1) 3 (1) 
Pleural effusion          
 All grades 18 (9) 5 (6) 23 (8) 5 (13) 12 (24) 1 (4) 18 (15) 16 (10) 57 (10) 
 Grade 3/4 4 (2) 2 (2) 6 (2) 2 (5) 2 (4) 4 (3) 7 (4) 17 (3) 

TEAEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.

Abbreviations are explained in Table 1.

*

The subgroups of patients with intolerance to prior TKI therapy.

Includes patients (n = 4) for whom prior imatinib therapy failed and who were intolerant to prior nilotinib therapy or resistant or intolerant to prior nilotinib and dasatinib therapy (because of low n, data not shown separately).

Individual hematologic TEAEs were clustered with the related terms from investigations.

Serious AEs occurred in 248 (44%) patients, more commonly in the ADV cohort (58%) vs CP2L (39%) and CP3L (34%) cohorts. The most frequently reported serious AEs (≥16 patients) were pneumonia (n = 29), pleural effusion (n = 23), pyrexia (n = 21), and thrombocytopenia (n = 16).

On-treatment grade 3/4 hematologic laboratory abnormalities were reported frequently, particularly in the ADV cohort (Table 4). Grade 3/4 nonhematologic laboratory abnormalities reported on treatment in ≥5% of patients included hypermagnesemia (10%), increased ALT (8%), hypophosphatemia (8%), and increased lipase (7%; Table 4). Grade 3/4 hypermagnesemia was more common in patients intolerant vs resistant to prior TKIs (CP2L or CP3L); hematologic laboratory abnormalities were more common in CP2L patients intolerant vs resistant to prior TKIs.

Table 4

Maximum on-treatment grade 3 and 4 laboratory abnormalities reported for ≥5% of patients

Laboratory abnormality, n (%) CP2L CP3L ADV (n = 166) Total (n = 570) 
IM-R (n = 196) IM-I (n = 90)* Total (n = 286) IM-R/I + D-R (n = 38) IM-R/I + D-I (n = 50)* IM-R/I + N-R (n = 26) Total† (n = 118) 
Hematologic          
 Thrombocytopenia          
  Grade 3 30 (15) 19 (21) 49 (17) 7 (18) 8 (16) 3 (12) 18 (15) 32 (19) 99 (17) 
  Grade 4 14 (7) 9 (10) 23 (8) 1 (3) 7 (14) 5 (19) 13 (11) 67 (40) 103 (18) 
 Lymphopenia          
  Grade 3 23 (12) 15 (17) 38 (13) 5 (13) 4 (8) 3 (12) 13 (11) 27 (16) 78 (14) 
  Grade 4 5 (3) 1 (1) 6 (2) 1 (3) 2 (4) 3 (12) 6 (5) 16 (10) 28 (5) 
 Neutropenia          
  Grade 3 20 (10) 16 (18) 36 (13) 5 (13) 4 (8) 2 (8) 11 (9) 25 (15) 72 (13) 
  Grade 4 7 (4) 6 (7) 13 (5) 2 (5) 6 (12) 4 (15) 13 (11) 42 (25) 68 (12) 
 Anemia          
  Grade 3 15 (8) 16 (18) 31 (11) 4 (11) 1 (4) 5 (4) 41 (25) 77 (14) 
  Grade 4 9 (5) 1 (1) 10 (3) 1 (3) 4 (8) 5 (4) 16 (10) 31 (5) 
 Leukopenia          
  Grade 3 13 (7) 10 (11) 23 (8) 1 (3) 4 (8) 5 (4) 28 (17) 56 (10) 
  Grade 4 20 (12) 20 (4) 
Nonhematologic          
 Hypermagnesemia          
  Grade 3 14 (7) 17 (19) 31 (11) 1 (3) 13 (26) 14 (12) 14 (8) 59 (10) 
  Grade 4 
 Increased ALT          
  Grade 3 19 (10) 10 (11) 29 (10) 2 (4) 4 (15) 6 (5) 9 (5) 44 (8) 
  Grade 4 1 (1) 2 (2) 3 (1) 1 (4) 1 (1) 4 (1) 
 Hypophosphatemia          
  Grade 3 20 (10) 7 (8) 27 (9) 3 (6) 1 (4) 4 (3) 12 (7) 43 (8) 
  Grade 4 1 (1) 1 (<1) 1 (1) 2 (<1) 
 Increased lipase          
  Grade 3 19 (10) 7 (8) 26 (9) 2 (5) 3 (6) 2 (8) 7 (6) 4 (2) 37 (6) 
  Grade 4 1 (1) 1 (1) 2 (1) 1 (2) 1 (1) 1 (1) 4 (1) 
 Hyperglycemia          
  Grade 3 4 (2) 5 (6) 9 (3) 1 (2) 1 (1) 10 (6) 20 (4) 
  Grade 4 1 (1) 1 (<1) 1 (<1) 
 Hyponatremia          
  Grade 3 2 (1) 3 (3) 5 (2) 1 (3) 1 (1) 10 (6) 16 (3) 
  Grade 4 4 (2) 4 (1) 4 (1) 
Laboratory abnormality, n (%) CP2L CP3L ADV (n = 166) Total (n = 570) 
IM-R (n = 196) IM-I (n = 90)* Total (n = 286) IM-R/I + D-R (n = 38) IM-R/I + D-I (n = 50)* IM-R/I + N-R (n = 26) Total† (n = 118) 
Hematologic          
 Thrombocytopenia          
  Grade 3 30 (15) 19 (21) 49 (17) 7 (18) 8 (16) 3 (12) 18 (15) 32 (19) 99 (17) 
  Grade 4 14 (7) 9 (10) 23 (8) 1 (3) 7 (14) 5 (19) 13 (11) 67 (40) 103 (18) 
 Lymphopenia          
  Grade 3 23 (12) 15 (17) 38 (13) 5 (13) 4 (8) 3 (12) 13 (11) 27 (16) 78 (14) 
  Grade 4 5 (3) 1 (1) 6 (2) 1 (3) 2 (4) 3 (12) 6 (5) 16 (10) 28 (5) 
 Neutropenia          
  Grade 3 20 (10) 16 (18) 36 (13) 5 (13) 4 (8) 2 (8) 11 (9) 25 (15) 72 (13) 
  Grade 4 7 (4) 6 (7) 13 (5) 2 (5) 6 (12) 4 (15) 13 (11) 42 (25) 68 (12) 
 Anemia          
  Grade 3 15 (8) 16 (18) 31 (11) 4 (11) 1 (4) 5 (4) 41 (25) 77 (14) 
  Grade 4 9 (5) 1 (1) 10 (3) 1 (3) 4 (8) 5 (4) 16 (10) 31 (5) 
 Leukopenia          
  Grade 3 13 (7) 10 (11) 23 (8) 1 (3) 4 (8) 5 (4) 28 (17) 56 (10) 
  Grade 4 20 (12) 20 (4) 
Nonhematologic          
 Hypermagnesemia          
  Grade 3 14 (7) 17 (19) 31 (11) 1 (3) 13 (26) 14 (12) 14 (8) 59 (10) 
  Grade 4 
 Increased ALT          
  Grade 3 19 (10) 10 (11) 29 (10) 2 (4) 4 (15) 6 (5) 9 (5) 44 (8) 
  Grade 4 1 (1) 2 (2) 3 (1) 1 (4) 1 (1) 4 (1) 
 Hypophosphatemia          
  Grade 3 20 (10) 7 (8) 27 (9) 3 (6) 1 (4) 4 (3) 12 (7) 43 (8) 
  Grade 4 1 (1) 1 (<1) 1 (1) 2 (<1) 
 Increased lipase          
  Grade 3 19 (10) 7 (8) 26 (9) 2 (5) 3 (6) 2 (8) 7 (6) 4 (2) 37 (6) 
  Grade 4 1 (1) 1 (1) 2 (1) 1 (2) 1 (1) 1 (1) 4 (1) 
 Hyperglycemia          
  Grade 3 4 (2) 5 (6) 9 (3) 1 (2) 1 (1) 10 (6) 20 (4) 
  Grade 4 1 (1) 1 (<1) 1 (<1) 
 Hyponatremia          
  Grade 3 2 (1) 3 (3) 5 (2) 1 (3) 1 (1) 10 (6) 16 (3) 
  Grade 4 4 (2) 4 (1) 4 (1) 

Abbreviations are explained in Table 1.

*

The subgroups of patients with intolerance to prior TKI therapy.

Includes patients (n = 4) for whom prior imatinib therapy failed and who were intolerant to prior nilotinib therapy or resistant or intolerant to prior nilotinib and dasatinib therapy (because of low n, data not shown separately).

Forty-four deaths (including 32 deaths in the ADV cohort) occurred within 30 days after the last bosutinib dose (supplemental Table A1, available on the Blood Web site). Common reasons included CML disease progression (n = 25 [4%]) and AEs considered unrelated to bosutinib by the investigators (n = 16 [3%]), most frequently pneumonia/pneumonitis (n = 5) and cardiac events (n = 6). Three deaths were attributed to an AE considered bosutinib-related by the investigator (lower gastrointestinal hemorrhage with thrombocytopenia [CP3L cohort], myocardial infarction [ADV], and acidosis [with respiratory failure complicated by sepsis; ADV]). All deaths in the CP2L cohort occurred in patients with resistance (not intolerance) to prior imatinib treatment; all deaths in the CP3L cohort occurred in patients with resistance or intolerance to prior dasatinib (not nilotinib) treatment (supplemental Table A1).

Characteristics and management of individual toxicities

Diarrhea occurred in 82% of all patients with little variability across patient cohorts. Diarrhea TEAEs were noted soon after bosutinib initiation, with a median time to first event of 2.0 days (Table 5). Diarrhea incidence decreased over time on treatment (supplemental Figure A1). Diarrhea TEAEs were predominantly of low severity and were typically transient, with a median duration of 1 to 2 days per event across cohorts. Diarrhea TEAEs were considered bosutinib-related in 455 (80%) patients, with <2% of bosutinib-related diarrhea AEs considered serious (n = 8). Concomitant antidiarrheal medication was used in 65% of patients who experienced diarrhea, representing the primary management strategy. Loperamide (58%; Imodium) was used most frequently. Less commonly, diarrhea was managed by bosutinib interruption (14%) and reduction (6%), allowing most affected patients to maintain their bosutinib dose. Few patients (1%) in the safety population discontinued treatment because of diarrhea, emphasizing the manageability of this toxicity in the majority of patients. Nearly all (97%) patients whose diarrhea was managed with temporary interruption of bosutinib dosing and who were subsequently rechallenged did not discontinue bosutinib because of diarrhea. Diarrhea characteristics were generally consistent across the 3 cohorts.

Table 5

Characteristics and management of diarrhea TEAEs

Parameter Total (n = 465) 
Median time to first event (range), d 2.0 (1-1330) 
Median duration of an event* (range), d 2.0 (1-1510) 
Diarrhea resolved, n (%) 387 (83) 
Diarrhea management, n (%)  
 Received dose reduction 26 (6) 
 Received dose interruption 65 (14) 
  No rechallenge 1 (2) 
  Rechallenge 64 (99) 
   Successful rechallenge† 62 (97) 
   Unsuccessful rechallenge‡ 2 (3) 
 Received concurrent medication 304 (65) 
 Permanent treatment discontinuation due to diarrhea§ 6/570 (1) 
Parameter Total (n = 465) 
Median time to first event (range), d 2.0 (1-1330) 
Median duration of an event* (range), d 2.0 (1-1510) 
Diarrhea resolved, n (%) 387 (83) 
Diarrhea management, n (%)  
 Received dose reduction 26 (6) 
 Received dose interruption 65 (14) 
  No rechallenge 1 (2) 
  Rechallenge 64 (99) 
   Successful rechallenge† 62 (97) 
   Unsuccessful rechallenge‡ 2 (3) 
 Received concurrent medication 304 (65) 
 Permanent treatment discontinuation due to diarrhea§ 6/570 (1) 
*

Event defined based on start to stop of diarrhea with no grade change; any change in grade represents a new event.

Successful rechallenge includes patients who did not experience subsequent/persistent diarrhea (n = 8) or experienced subsequent diarrhea that did not lead to treatment discontinuation (n = 54).

Unsuccessful rechallenge indicates treatment discontinuation due to diarrhea following rechallenge with bosutinib.

§

Includes patients with no rechallenge or unsuccessful rechallenge following dose interruption, as well as those who discontinued treatment because of diarrhea without dose interruption.

Pleural effusion TEAEs occurred in 57 patients (10%) in the safety population, including 17 (3%) with maximum toxicity grade of 3 (n = 15), 4 (n = 1), or 5 (n = 1; CP2L, death on study day 2290 due to congestive heart failure and pleural effusion, both unrelated to bosutinib). Twenty-one patients (4%) experienced a serious pleural effusion TEAE. Among the 3 cohorts, pleural effusions were more common in the CP3L (all grades, n = 18 of 118 [15%]; grade 3/4/5, 4 of 118 [3%]) vs CP2L (n = 23 of 286 [8%] and n = 6 of 286 [2%], respectively) and ADV (n = 16 of 166 [10%] and 7 of 166 [4%]) cohorts. Median time to onset of the first pleural effusion was 541 (range, 3-1993) days; median event duration was 21 (range, 1-421) days. Of patients who experienced pleural effusion, 26% had dose reductions, 47% had dose interruptions, and 58% were managed with concurrent medications. Four (1%) patients discontinued bosutinib because of pleural effusion.

Of 57 patients with pleural effusion during bosutinib treatment, 22 (39%) had a history of pleural effusion, of whom 16 attributed prior TKI discontinuation to pleural effusion (dasatinib, n = 14; imatinib and nilotinib, n = 1 each). Of 17 CP3L patients with prior dasatinib treatment who experienced pleural effusion during bosutinib treatment, 11 (65%) indicated pleural effusion as the reason for dasatinib intolerance. Most patients (n = 33 of 57 [58%]) with pleural effusions during bosutinib treatment had never been exposed to dasatinib.

The collective incidence of cardiac-related TEAEs (combined analysis of MedDRA system organ class Cardiac Disorders and Investigations [cardiac and vascular terms]) was relatively low (18% of patients experienced any cardiac event, of whom most presented with prior or ongoing cardiac disorders at screening), with most patients (10%) experiencing maximum grade 1 or 2 events, 5% maximum grade 3 events, 2% maximum grade 4 events, and 1% grade 5 events (including death due to myocardial infarction [n = 3], congestive cardiac failure [n = 2], and cardiac failure and coronary artery disease [n = 1 each]). The most common cardiac events were pericardial effusion (3%), atrial fibrillation, congestive cardiac failure, tachycardia, and palpitations (2% each). In the overall population, 33 of 570 (6%) patients experienced cardiac events considered bosutinib-related; 13 patients (2%) had treatment-related grade 3/4 events. Management of cardiac TEAEs included bosutinib dose interruption (24%) or reduction (7%); 40% received concomitant medication. Few patients (n = 12 [2%]) in the safety population discontinued treatment due to cardiac events. Of patients whose cardiac TEAE was managed with dose interruption, 19 of 24 (79%) were rechallenged with bosutinib; only 4 rechallenged patients subsequently discontinued bosutinib due to a cardiac event.

Based on ECG laboratory data, only 1 patient experienced on-treatment grade 3 Fridericia corrected QT interval prolongation (patient had eligibility violation of grade 2 prolongation at baseline). Based on echocardiogram/multiple gated acquisition scan analysis, 1 patient had a shift in left ventricular ejection fraction (LVEF) decrease from normal (baseline) to grade 3 (on treatment); 3 patients had grade 3 LVEF at baseline that continued on therapy; 1 patient had on-treatment grade 3 LVEF with no available baseline results.

Overall, cardiac-related toxicities on bosutinib were infrequent, occurred mostly in patients with preexisting cardiac conditions reported at baseline, and were manageable with dose interruption and/or reduction and concomitant medication.

Relatively few vascular disorders (MedDRA system organ class) were observed (overall, 76 [13%]; treatment related, 18 [3%]). Hypertension was the most frequent TEAE (any grade, 37 [6%]; grade 3/4, 11 [2%]); for all other vascular events, frequency was ≤2%. Notably, 1 event of peripheral arterial occlusive disease (grade 2) was reported in a CP3L patient with prior nilotinib exposure; the event was considered serious, unrelated to bosutinib, and resolved within 10 days.

Myelosuppression (ie, anemia, neutropenia, and thrombocytopenia) was reported frequently; thrombocytopenia was the most commonly observed grade 3/4 TEAE (Table 3) and grade 3/4 laboratory abnormality (Table 4). Several patients with grade 3/4 laboratory abnormalities on treatment had baseline grade 3/4 hematologic laboratory abnormalities (thrombocytopenia, n = 56 of 202 [28%]; neutropenia, n = 30 of 140 [21%]; anemia, n = 15 of 108 [14%]; supplemental Table A2).

Median time to first myelosuppression TEAE was 22.0 days across cohorts (Table 6). Myelosuppression TEAEs were generally transient; median event duration was 14.0 days (range, 1-1373 days). Myelosuppression events were managed primarily with bosutinib treatment modifications; 46% of affected patients temporarily stopped treatment, 32% underwent dose reduction. Across cohorts, 10% of affected patients received growth factor support; 1% underwent transfusion for management of ≥1 event. Although these events represented the most severe toxicities, only 7% of patients in the safety population discontinued treatment because of a myelosuppression TEAE, suggesting overall manageability and tolerability of these events.

Table 6

Characteristics and management of myelosuppression TEAEs

Parameter All grades Grade 3/4 
CP2L (n = 157) CP3L (n = 56) ADV (n = 106) Total (n = 319) Total (n = 231) 
Median time to first event (range), d 29.0 (1-1767) 28.0 (1-1202) 14.0 (1-899) 22.0 (1-1767) 29.0 (1-1767) 
Median duration of an event (range), d 15.0 (1-1373) 15.0 (1-454) 8.0 (1-889) 14.0 (1-1373) 9.0 (1-889) 
Myelosuppression resolved, n (%) 85 (54) 34 (61) 52 (49) 171 (54) 163 (71) 
Myelosuppression management, n (%)      
 Received dose reduction 56 (36) 21 (38) 25 (24) 102 (32) 60 (26) 
 Received dose interruption 74 (47) 33 (59) 38 (36) 145 (46) 138 (60) 
 Received concurrent medication 22 (14) 13 (23) 26 (25) 61 (19) 46 (20) 
  Received transfusion(s) 1 (2) 1 (1) 2 (1) 1 (<1) 
  Received growth factor(s) 10 (6) 10 (18) 13 (12) 33 (10) 26 (11) 
 Permanent treatment discontinuation due to myelosuppression* 20/286 (7) 14/118 (12) 6/166 (4) 40/570 (7) 33/570 (6) 
Parameter All grades Grade 3/4 
CP2L (n = 157) CP3L (n = 56) ADV (n = 106) Total (n = 319) Total (n = 231) 
Median time to first event (range), d 29.0 (1-1767) 28.0 (1-1202) 14.0 (1-899) 22.0 (1-1767) 29.0 (1-1767) 
Median duration of an event (range), d 15.0 (1-1373) 15.0 (1-454) 8.0 (1-889) 14.0 (1-1373) 9.0 (1-889) 
Myelosuppression resolved, n (%) 85 (54) 34 (61) 52 (49) 171 (54) 163 (71) 
Myelosuppression management, n (%)      
 Received dose reduction 56 (36) 21 (38) 25 (24) 102 (32) 60 (26) 
 Received dose interruption 74 (47) 33 (59) 38 (36) 145 (46) 138 (60) 
 Received concurrent medication 22 (14) 13 (23) 26 (25) 61 (19) 46 (20) 
  Received transfusion(s) 1 (2) 1 (1) 2 (1) 1 (<1) 
  Received growth factor(s) 10 (6) 10 (18) 13 (12) 33 (10) 26 (11) 
 Permanent treatment discontinuation due to myelosuppression* 20/286 (7) 14/118 (12) 6/166 (4) 40/570 (7) 33/570 (6) 

Myelosuppression events include anemia, hemoglobin decreased, neutropenia, neutrophil count decreased, thrombocytopenia, and platelet count decreased.

Abbreviations are explained in Table 1.

*

Includes patients with no rechallenge or unsuccessful rechallenge following dose interruption as well as those who discontinued treatment due to myelosuppression without dose interruption.

Across cohorts, ALT and aspartate aminotransferase (AST) elevation TEAEs were reported in 99 patients (17%) and 81 patients (14%), respectively; 112 patients (20%) had either or both types of elevation. Maximum grade 3 ALT/AST TEAEs were reported in 39 patients (7%); maximum grade 4 TEAEs were reported in 2 patients (<1%). Median time to first ALT/AST TEAE was 33.5 days; median event duration was 21.0 days. Despite the relative frequency of ALT and AST elevations, relatively few patients (13 [2%]) discontinued treatment because of these events (Table 7). The incidence of ALT events decreased over time on treatment (supplemental Figure A2). ALT and AST TEAEs were primarily managed with bosutinib dose reduction or temporary interruption (18% and 35%, respectively, of affected patients). Among patients who required a temporary dose interruption for ALT and/or AST elevation and were subsequently rechallenged with bosutinib, 9 of 35 (26%) discontinued bosutinib due to ALT/AST elevation. ALT and AST elevation TEAEs were managed with concomitant medication in 13% of affected patients.

Table 7

Characteristics and management of ALT and AST TEAEs

Parameter ALT elevation (n = 99) AST elevation (n = 81) ALT or AST elevation (n = 112) 
Median time to first event
(range), d 
30 (6-841) 33 (1-1400) 33.5 (1-1400) 
Median duration of event
(range), d 
21 (1-1714) 20 (1-803) 21.0 (1-1714) 
Events resolved, n (%) 84 (85) 69 (85) 94 (84) 
Event management, n (%)    
 Received dose reduction 17 (17) 7 (9) 20 (18) 
 Received dose interruption 39 (39) 28 (35) 39 (35) 
  No rechallenge 4 (10) 7 (25) 4 (10) 
  Rechallenge 35 (90) 21 (75) 35 (90) 
   Successful rechallenge* 26 (74) 19 (90) 26 (74) 
   Unsuccessful rechallenge† 9 (26) 2 (10) 9 (26) 
 Received concurrent medication‡ 12 (12) 10 (12) 14 (13) 
 Permanent treatment discontinuation due to event§ 12/570 (2) 4/570 (1) 13/570 (2) 
Parameter ALT elevation (n = 99) AST elevation (n = 81) ALT or AST elevation (n = 112) 
Median time to first event
(range), d 
30 (6-841) 33 (1-1400) 33.5 (1-1400) 
Median duration of event
(range), d 
21 (1-1714) 20 (1-803) 21.0 (1-1714) 
Events resolved, n (%) 84 (85) 69 (85) 94 (84) 
Event management, n (%)    
 Received dose reduction 17 (17) 7 (9) 20 (18) 
 Received dose interruption 39 (39) 28 (35) 39 (35) 
  No rechallenge 4 (10) 7 (25) 4 (10) 
  Rechallenge 35 (90) 21 (75) 35 (90) 
   Successful rechallenge* 26 (74) 19 (90) 26 (74) 
   Unsuccessful rechallenge† 9 (26) 2 (10) 9 (26) 
 Received concurrent medication‡ 12 (12) 10 (12) 14 (13) 
 Permanent treatment discontinuation due to event§ 12/570 (2) 4/570 (1) 13/570 (2) 
*

Successful rechallenge includes patients who did not experience subsequent ALT or AST AEs (n = 4 and n = 6, respectively) or experienced subsequent ALT and AST AEs that did not lead to treatment discontinuation (n = 22 and n = 13).

Unsuccessful rechallenge indicates treatment discontinuation due to ALT or AST elevation following rechallenge with bosutinib.

Concurrent medications used for management of ALT and/or AST elevations included essential phospholipids, ursodiol, steroids, S-adenosylmethionine, milk thistle extract, and glycyrrhizic acid. Patients may have received ≥1 medication.

§

Includes patients with no rechallenge or unsuccessful rechallenge following dose interruption, as well as those who discontinued treatment due to ALT or AST elevation without dose interruption.

Discussion

This analysis comprehensively assessed toxicities and toxicity management associated with long-term bosutinib therapy (CP2L, 4-year minimum follow-up [unless discontinued earlier]: CP3L and ADV, 3-year minimum follow-up [unless discontinued earlier]) in patients with Ph+ leukemia resistant or intolerant to prior TKI therapy. Overall, bosutinib tolerability did not differ substantially among Ph+ leukemia patients, regardless of disease phase and treatment line. Within second-line and third-/fourth-line CP CML cohorts, dose reductions/interruptions and treatment discontinuation due to AEs, particularly thrombocytopenia, were more common in patients intolerant vs resistant to prior TKIs; in the CP2L cohort, patients intolerant to prior TKI therapy had 0 deaths in 90 patients within 30 days of last dose vs 7 in 196 for patients resistant to prior TKI therapy. Among all cohorts, the percentage of patients discontinuing bosutinib because of AEs in this analysis (CP2L, 22%; CP3L, 25%; ADV, 18%) was similar to that reported for first-line bosutinib therapy in the phase 3 Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial (19%) with a median bosutinib treatment duration of 13.8 months.19 

Gastrointestinal events, particularly diarrhea, were the most commonly reported TEAEs (all grades, grade 3/4). Although diarrhea occurred in most patients (CP2L, 86%; CP3L, 83%; ADV, 74%), events were typically transient and of mild to moderate severity, with most patients experiencing diarrhea early after treatment initiation (median time to first event, 2.0 days) and few treatment-related events reported as serious. Gastrointestinal AEs (diarrhea/nausea/vomiting) were less frequently reported in patients with imatinib-resistant/intolerant CP CML previously treated with dasatinib 100 mg per day (25%/18%/7%, respectively)19  or nilotinib (12%/25%/13%).20  These gastrointestinal AEs occurred more frequently in the CP2L (86%/46%/37%) and CP3L (83%/48%/38%) CML cohorts in the present analysis than in patients receiving first-line bosutinib treatment (68%/31%/32%).19  Diarrhea AEs associated with bosutinib in all lines of therapy were manageable with concurrent medications and dose interruptions and/or reductions. No patients discontinued therapy primarily because of diarrhea in the first-line setting,19  and only 1% of patients receiving bosutinib second-line (or later) discontinued due to diarrhea. Among patients who had dose interruption due to diarrhea and were subsequently redosed, 97% were successfully rechallenged with bosutinib. These data suggest bosutinib remains well tolerated despite the relatively high incidence of gastrointestinal events. With proper management, these events are transient and mild for most patients.

Treatment-related pleural effusion is associated with dasatinib (all grades, 14%) in patients with imatinib-resistant/intolerant CP CML,20  but not nilotinib (all grades, 1%).21  In our study, pleural effusion TEAEs occurred in relatively few CP CML patients with imatinib resistance/intolerance (CP2L cohort, 8%) and overall (10%) during bosutinib treatment. The proportion of patients experiencing pleural effusion was highest in the CP3L cohort (n = 18 [15%]), and the majority (17 of 18) of affected patients received prior dasatinib. Furthermore, 11 of these 17 patients reported pleural effusion as the reason for dasatinib intolerance. Notably, pleural effusions rarely led to bosutinib discontinuation (1%).

Cardiac and vascular events were observed at relatively low frequency in this study (any cause, 18% and 13%, respectively; treatment-related, 6% and 3%), with low incidences of individual events (≤3% and ≤6%). The majority of patients requiring dose interruption for cardiac toxicity were successfully rechallenged; 2% of patients discontinued bosutinib for cardiac-related events. Notably, the incidence of drug-related cardiac AEs in first-line CP CML patients was also low (4%).19 

In our study, the most common grade 3/4 TEAEs and laboratory abnormalities were myelosuppression events, which is unsurprising because myelosuppression is commonly associated with other BCR-ABL TKIs (dasatinib and nilotinib) as second-line CML treatment.16-18  In a phase 3 trial of dasatinib in patients with imatinib-resistant/intolerant CP CML, reported rates of grade 3/4 treatment-related myelosuppression laboratory abnormalities were 35% for neutropenia, 23% for thrombocytopenia, and 13% for anemia after a median treatment duration of 22 months.20  Similarly, a phase 2 trial of nilotinib in imatinib-resistant/intolerant CP CML reported incidences of grade 3/4 laboratory abnormalities of 31% for neutropenia, 30% for thrombocytopenia, and 11% for anemia.21  Rates of grade 3/4 laboratory abnormalities of neutropenia were lower with bosutinib in both the CP2L (17%) and CP3L (20%) cohorts vs dasatinib and nilotinib, whereas rates of thrombocytopenia (CP2L, 25%; CP3L, 26%) and anemia (CP2L, 14%; CP3L, 8%) were fairly similar. The incidences of grade 3/4 myelosuppression laboratory abnormalities with bosutinib were higher in ADV patients (thrombocytopenia, 60%; neutropenia, 41%; anemia, 35%) than in CP CML patients. Myelosuppression was managed with bosutinib dose modifications and less frequently with transfusions and growth factors; myelosuppression events were the primary reason for treatment discontinuation in 7% of patients. Myelosuppression grade 3/4 laboratory abnormalities with bosutinib were lower (14% for thrombocytopenia, 11% for neutropenia, 6% for anemia) with first-line therapy.19 

ALT and AST elevation TEAEs in our study were typically well tolerated; few patients (2%) discontinued treatment because of these TEAEs. The percentage of affected patients with bosutinib dose interruptions (35%) or reductions (18%) due to ALT or AST elevation was lower in our analysis vs first-line therapy (57% and 36%, respectively).19  In our analysis, the majority (74%) of patients subsequently rechallenged with bosutinib following dose interruption due to ALT and/or AST elevation did not discontinue treatment because of ALT/AST elevation, again suggesting that these toxicities, while notable and requiring monitoring, were manageable.

Generally, bosutinib demonstrated acceptable tolerability in patients with Ph+ CML and ALL, with an AE profile distinct from that of other TKIs. Toxicities observed with bosutinib treatment were generally manageable with treatment modification and/or concomitant medication. Additional experience with bosutinib treatment may further improve the management of observed toxicities. Our findings support the continued clinical development of bosutinib as monotherapy for the treatment of Ph+ CML patients.

Presented in part in abstract form at the annual meeting of the American Society of Hematology, December 7-10, 2013, New Orleans, LA.

The online version of this article contains a data supplement.

There is an Inside Blood commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

Acknowledgments

We acknowledge all of the participating patients and their families as well as the global network of investigators, research nurses, study coordinators, and operations staff.

This study was sponsored by Wyeth Research, which was acquired by Pfizer Inc. in October 2009. Programming support was provided by Gaurav Rathi of Pfizer Inc. Editorial/medical writing support was provided by Kimberly Brooks of SciFluent, Cynthia Gobbel of Complete Healthcare Communications, and Tiffany Brake of Complete Healthcare Communications, and was funded by Pfizer Inc.

Authorship

Contribution: J.E.C., H.J.K., and C.G.-P. contributed to the study design; J.E.C., D.-W.K., T.H.B., G.M., N.B., and K.T. collected and assembled the data; H.M.K., J.E.C., D.-W.K., H.J.K., T.H.B., K.P., G.M., S.D., E.L., V.K., K.T., N.B., and C.G.-P. contributed to the analysis and/or interpretation of data; H.M.K., J.E.C., D.-W.K., H.J.K., T.H.B., K.P., G.M., S.D., and C.G.-P. provided study materials and/or enrolled patients in the study; E.L. performed statistical analyses; and all authors assisted in the writing and/or critical review of the manuscript and approved the final version of the manuscript for submission.

Conflict-of-interest disclosure: The study was sponsored by Pfizer Inc. H.M.K. received research funding from Pfizer. J.E.C. has served as an advisor/consultant for and received research funding from Ariad, Bristol-Myers Squibb, Chemgenex, Novartis, and Pfizer. D.-W.K. has served as an advisor/consultant for and received research funding and honoraria from Bristol-Myers Squibb, Novartis, and Pfizer. H.J.K. has served as an advisor/consultant for Pfizer. T.H.B. has served as an advisor/consultant for and received honoraria from Ariad, Bristol-Myers Squibb, Novartis, and Pfizer, and has also received research funding from Novartis. K.P. has served as an advisor/consultant for and received research funding and honoraria from Bristol-Myers Squibb and Novartis. G.M. has served as an advisor/consultant for and received honoraria from Bristol-Myers Squibb and Novartis. S.D. has served as an advisor/consultant for and received research funding from Pfizer. E.L. is a current employee of Pfizer, and V.K. and N.B. are former employees of Pfizer. K.T. was an employee of Inventiv, who was a paid consultant to Pfizer in the support of this study and development of this manuscript. K.T. is currently an employee of Pfizer. C.G.-P. has served as an advisor/consultant for and received research funding from Pfizer.

Correspondence: Hagop M. Kantarjian, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030; e-mail: hkantarjian@mdanderson.org.

References

References
1
Baccarani
M
Deininger
MW
Rosti
G
, et al. 
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Blood
2013
, vol. 
122
 
6
(pg. 
872
-
884
)
2
National Comprehensive Cancer Network
 
NCCN Clinical Practice Guidelines in Oncology™. Chronic Myelogenous Leukemia. Version 1. 2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed October 3, 2013
3
National Comprehensive Cancer Network
 
NCCN Clinical Practice Guidelines in Oncology™. Acute Lymphoblastic Leukemia. Version 1. 2013. Available at: http://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed October 3, 2013
4
O’Brien
SG
Guilhot
F
Larson
RA
, et al. 
for the IRIS Investigators
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
N Engl J Med
2003
, vol. 
348
 
11
(pg. 
994
-
1004
)
5
de Lavallade
H
Apperley
JF
Khorashad
JS
, et al. 
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
J Clin Oncol
2008
, vol. 
26
 
20
(pg. 
3358
-
3363
)
6
Deininger
MW
O’Brien
SG
Ford
JM
Druker
BJ
Practical management of patients with chronic myeloid leukemia receiving imatinib.
J Clin Oncol
2003
, vol. 
21
 
8
(pg. 
1637
-
1647
)
7
Weisberg
E
Manley
PW
Cowan-Jacob
SW
Hochhaus
A
Griffin
JD
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
Nat Rev Cancer
2007
, vol. 
7
 
5
(pg. 
345
-
356
)
8
Ramirez
P
DiPersio
JF
Therapy options in imatinib failures.
Oncologist
2008
, vol. 
13
 
4
(pg. 
424
-
434
)
9
Kantarjian
HM
Shah
NP
Cortes
JE
, et al. 
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Blood
2012
, vol. 
119
 
5
(pg. 
1123
-
1129
)
10
Kantarjian
HM
Hochhaus
A
Saglio
G
, et al. 
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Lancet Oncol
2011
, vol. 
12
 
9
(pg. 
841
-
851
)
11
Puttini
M
Coluccia
AM
Boschelli
F
, et al. 
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
Cancer Res
2006
, vol. 
66
 
23
(pg. 
11314
-
11322
)
12
Remsing Rix
LL
Rix
U
Colinge
J
, et al. 
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Leukemia
2009
, vol. 
23
 
3
(pg. 
477
-
485
)
13
BOSULIF® (bosutinib). Full prescribing information. New York, NY: Pfizer Labs; 2012
14
Cortes
JE
Kantarjian
HM
Brümmendorf
TH
, et al. 
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Blood
2011
, vol. 
118
 
17
(pg. 
4567
-
4576
)
15
Khoury
HJ
Cortes
JE
Kantarjian
HM
, et al. 
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Blood
2012
, vol. 
119
 
15
(pg. 
3403
-
3412
)
16
TASIGNA® (nilotinib). Full prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007
17
SPRYCEL® (dasatinib). Full prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2009
18
GLEEVEC® (imatinib mesylate). Full prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009
19
Cortes
JE
Kim
DW
Kantarjian
HM
, et al. 
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
J Clin Oncol
2012
, vol. 
30
 
28
(pg. 
3486
-
3492
)
20
Shah
NP
Kim
DW
Kantarjian
H
, et al. 
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
Haematologica
2010
, vol. 
95
 
2
(pg. 
232
-
240
)
21
Kantarjian
HM
Giles
FJ
Bhalla
KN
, et al. 
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Blood
2011
, vol. 
117
 
4
(pg. 
1141
-
1145
)